{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:41:43Z","timestamp":1793155303477,"version":"4.5.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"crossref","award":["2022J01286"],"award-info":[{"award-number":["2022J01286"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Major Scientific Research Program for Young and Middle-aged Health Professionals of Fujian Province","award":["2023ZQNKD013"],"award-info":[{"award-number":["2023ZQNKD013"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"DOI":"10.1186\/s13058-026-02289-6","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T20:44:04Z","timestamp":1776890644000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The absence of B7-H4 inhibits PD-L1 expression by driving a methylation of PD-L1 promoter in breast cancer cells"],"prefix":"10.1186","volume":"28","author":[{"given":"Linlin","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jichun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiongwen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonglei","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Wei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"2289_CR1","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1146\/annurev.immunol.23.021704.115611","volume":"23","author":"RJ Greenwald","year":"2005","unstructured":"Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 2005;23:515\u201348. https:\/\/doi.org\/10.1146\/annurev.immunol.23.021704.115611.","journal-title":"Annu Rev Immunol"},{"issue":"8","key":"2289_CR2","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1007\/s00262-012-1293-6","volume":"61","author":"B Seliger","year":"2012","unstructured":"Seliger B, Quandt D. The expression, function, and clinical relevance of B7 family members in cancer. Cancer Immunol Immunother. 2012;61(8):1327\u201341. https:\/\/doi.org\/10.1007\/s00262-012-1293-6.","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"2289_CR3","doi-asserted-by":"publisher","first-page":"e1207841","DOI":"10.1080\/2162402X.2016.1207841","volume":"5","author":"Z Xu","year":"2016","unstructured":"Xu Z, Shen J, Wang MH, et al. Comprehensive molecular profiling of the B7 family of immune-regulatory ligands in breast cancer. Oncoimmunology. 2016;5(8):e1207841. https:\/\/doi.org\/10.1080\/2162402X.2016.1207841.","journal-title":"Oncoimmunology"},{"issue":"1","key":"2289_CR4","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s12935-024-03392-4","volume":"24","author":"J Liu","year":"2024","unstructured":"Liu J, Wang C, Jiang Y, Zhou Y, Chen L, Qian Z, Liu L, Wu D, Zhang Y. Comprehensive characterization of B7 family members in breast cancer: B7-H5 switch reverses breast cancer from immuno-cold into immuno-hot status. Cancer Cell Int. 2024;24(1):205. https:\/\/doi.org\/10.1186\/s12935-024-03392-4.","journal-title":"Cancer Cell Int"},{"issue":"12","key":"2289_CR5","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1158\/2159-8290.CD-20-0402","volume":"10","author":"X Song","year":"2020","unstructured":"Song X, Zhou Z, Li H, et al. Pharmacologic Suppression of B7-H4 Glycosylation Restores Antitumor Immunity in Immune-Cold Breast Cancers. Cancer Discov. 2020;10(12):1872\u201393. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0402.","journal-title":"Cancer Discov"},{"issue":"12","key":"2289_CR6","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1158\/1078-0432.CCR-15-2440","volume":"23","author":"HL MacGregor","year":"2017","unstructured":"MacGregor HL, Ohashi PS. Molecular Pathways: Evaluating the Potential for B7-H4 as an Immunoregulatory Target. Clin Cancer Res. 2017;23(12):2934\u201341. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2440.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2289_CR7","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1158\/1078-0432.CCR-04-1658","volume":"11","author":"B Tringler","year":"2005","unstructured":"Tringler B, Zhuo S, Pilkington G, Torkko KC, Singh M, Lucia MS, Heinz DE, Papkoff J, Shroyer KR. B7-h4 is highly expressed in ductal and lobular breast cancer. Clin Cancer Res. 2005;11(5):1842\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-1658.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2289_CR8","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00262-019-02451-4","volume":"69","author":"L Zhou","year":"2020","unstructured":"Zhou L, Ruan M, Liu Y, Zhu Y, Fu D, Wu K, Zhang Q. B7H4 expression in tumor cells impairs CD8 T cell responses and tumor immunity. Cancer Immunol Immunother. 2020;69(2):163\u201374. https:\/\/doi.org\/10.1007\/s00262-019-02451-4.","journal-title":"Cancer Immunol Immunother"},{"key":"2289_CR9","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41523-018-0095-1","volume":"4","author":"M Altan","year":"2018","unstructured":"Altan M, Kidwell KM, Pelekanou V, et al. Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. NPJ Breast Cancer. 2018;4:40. https:\/\/doi.org\/10.1038\/s41523-018-0095-1.","journal-title":"NPJ Breast Cancer"},{"issue":"8","key":"2289_CR10","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","volume":"8","author":"H Dong","year":"2002","unstructured":"Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793\u2013800. https:\/\/doi.org\/10.1038\/nm730.","journal-title":"Nat Med"},{"issue":"11","key":"2289_CR11","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1136\/jcp-2023-208942","volume":"77","author":"SA Saastad","year":"2024","unstructured":"Saastad SA, Skjervold AH, Ytterhus B, Engstrom MJ, Bofin AM. PD-L1 protein expression in breast cancer. J Clin Pathol. 2024;77(11):730\u20136. https:\/\/doi.org\/10.1136\/jcp-2023-208942.","journal-title":"J Clin Pathol"},{"issue":"4","key":"2289_CR12","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1158\/2326-6066.CIR-13-0127","volume":"2","author":"EA Mittendorf","year":"2014","unstructured":"Mittendorf EA, Philips AV, Meric-Bernstam F, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014;2(4):361\u201370. https:\/\/doi.org\/10.1158\/2326-6066.CIR-13-0127.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"2289_CR13","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s12943-024-02176-8","volume":"23","author":"M Jin","year":"2024","unstructured":"Jin M, Fang J, Peng J, et al. PD-1\/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies. Mol Cancer. 2024;23(1):266. https:\/\/doi.org\/10.1186\/s12943-024-02176-8.","journal-title":"Mol Cancer"},{"issue":"4","key":"2289_CR14","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1172\/JCI96313","volume":"129","author":"T Gruosso","year":"2019","unstructured":"Gruosso T, Gigoux M, Manem VSK, et al. Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers. J Clin Invest. 2019;129(4):1785\u2013800. https:\/\/doi.org\/10.1172\/JCI96313.","journal-title":"J Clin Invest"},{"issue":"6","key":"2289_CR15","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s12282-023-01498-7","volume":"30","author":"F Sanuki","year":"2023","unstructured":"Sanuki F, Mikami Y, Nishimura H, Fujita Y, Monobe Y, Nomura T, Taira N, Moriya T. Immunohistological analysis of B7-H4, IDO1, and PD-L1 expression and tumor immune microenvironment based on triple-negative breast cancer subtypes. Breast Cancer. 2023;30(6):1041\u201353. https:\/\/doi.org\/10.1007\/s12282-023-01498-7.","journal-title":"Breast Cancer"},{"issue":"3","key":"2289_CR16","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.ygyno.2017.03.006","volume":"145","author":"A Bregar","year":"2017","unstructured":"Bregar A, Deshpande A, Grange C, et al. Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors. Gynecol Oncol. 2017;145(3):446\u201352. https:\/\/doi.org\/10.1016\/j.ygyno.2017.03.006.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"2289_CR17","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13058-023-01721-5","volume":"25","author":"L Zhou","year":"2023","unstructured":"Zhou L, Wu J, Ruan M, Xiao Y, Lan H, Wu Q, Yu CW, Zhang Q. The loss of B7-H4 expression in breast cancer cells escaping from T cell cytotoxicity contributes to epithelial-to-mesenchymal transition. Breast Cancer Res. 2023;25(1):115. https:\/\/doi.org\/10.1186\/s13058-023-01721-5.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"2289_CR18","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1038\/s41467-021-22024-3","volume":"12","author":"L Garcia-Martinez","year":"2021","unstructured":"Garcia-Martinez L, Zhang Y, Nakata Y, Chan HL, Morey L. Epigenetic mechanisms in breast cancer therapy and resistance. Nat Commun. 2021;12(1):1786. https:\/\/doi.org\/10.1038\/s41467-021-22024-3.","journal-title":"Nat Commun"},{"key":"2289_CR19","doi-asserted-by":"publisher","first-page":"107205","DOI":"10.1016\/j.phrs.2024.107205","volume":"204","author":"L Zhou","year":"2024","unstructured":"Zhou L, Yu CW. Epigenetic modulations in triple-negative breast cancer: Therapeutic implications for tumor microenvironment. Pharmacol Res. 2024;204:107205. https:\/\/doi.org\/10.1016\/j.phrs.2024.107205.","journal-title":"Pharmacol Res"},{"key":"2289_CR20","doi-asserted-by":"publisher","first-page":"116559","DOI":"10.1016\/j.biopha.2024.116559","volume":"174","author":"L Trnkova","year":"2024","unstructured":"Trnkova L, Buocikova V, Mego M, Cumova A, Burikova M, Bohac M, Miklikova S, Cihova M, Smolkova B. Epigenetic deregulation in breast cancer microenvironment: Implications for tumor progression and therapeutic strategies. Biomed Pharmacother. 2024;174:116559. https:\/\/doi.org\/10.1016\/j.biopha.2024.116559.","journal-title":"Biomed Pharmacother"},{"key":"2289_CR21","doi-asserted-by":"publisher","first-page":"3958908","DOI":"10.1155\/2019\/3958908","volume":"2019","author":"P Darvin","year":"2019","unstructured":"Darvin P, Sasidharan Nair V, Elkord E. PD-L1 Expression in Human Breast Cancer Stem Cells Is Epigenetically Regulated through Posttranslational Histone Modifications. J Oncol. 2019;2019:3958908. https:\/\/doi.org\/10.1155\/2019\/3958908.","journal-title":"J Oncol"},{"key":"2289_CR22","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13148-018-0512-1","volume":"10","author":"V Sasidharan Nair","year":"2018","unstructured":"Sasidharan Nair V, El Salhat H, Taha RZ, John A, Ali BR, Elkord E. DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer. Clin Epigenetics. 2018;10:78. https:\/\/doi.org\/10.1186\/s13148-018-0512-1.","journal-title":"Clin Epigenetics"},{"issue":"6","key":"2289_CR23","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/nprot.2008.73","volume":"3","author":"TD Schmittgen","year":"2008","unstructured":"Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3(6):1101\u20138. https:\/\/doi.org\/10.1038\/nprot.2008.73.","journal-title":"Nat Protoc"},{"issue":"11","key":"2289_CR24","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1093\/bioinformatics\/18.11.1427","volume":"18","author":"LC Li","year":"2002","unstructured":"Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics. 2002;18(11):1427\u201331. https:\/\/doi.org\/10.1093\/bioinformatics\/18.11.1427.","journal-title":"Bioinformatics"},{"key":"2289_CR25","doi-asserted-by":"publisher","first-page":"145376","DOI":"10.1016\/j.gene.2020.145376","volume":"772","author":"M Amini","year":"2021","unstructured":"Amini M, Hejazi M, Ghorban K, Mokhtarzadeh A, Baradaran B. Identification of functional methylated CpG loci in PD-L1 promoter as the novel epigenetic biomarkers for primary gastric cancer. Gene. 2021;772:145376. https:\/\/doi.org\/10.1016\/j.gene.2020.145376.","journal-title":"Gene"},{"issue":"100","key":"2289_CR26","doi-asserted-by":"publisher","first-page":"eado8758","DOI":"10.1126\/sciimmunol.ado8758","volume":"9","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Zhang Y, Li M, et al. Oncogenic KRAS drives immunosuppression of colorectal cancer by impairing DDX60-mediated dsRNA accumulation and viral mimicry. Sci Immunol. 2024;9(100):eado8758. https:\/\/doi.org\/10.1126\/sciimmunol.ado8758.","journal-title":"Sci Immunol"},{"key":"2289_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-025-01569-4","author":"C Yang","year":"2025","unstructured":"Yang C, Guo S, Ye K, et al. A trispecific antibody engaging T cells with tumour and myeloid cells augments antitumour immunity. Nat Biomed Eng. 2025. https:\/\/doi.org\/10.1038\/s41551-025-01569-4.","journal-title":"Nat Biomed Eng"},{"key":"2289_CR28","doi-asserted-by":"publisher","first-page":"107473","DOI":"10.1016\/j.intimp.2021.107473","volume":"94","author":"C Yu","year":"2021","unstructured":"Yu C, Zhou L, Zhang Q. Identification of unanimous immune subtypes for different hormone receptor phenotypes of human breast cancer with potential prognostic significance. Int Immunopharmacol. 2021;94:107473. https:\/\/doi.org\/10.1016\/j.intimp.2021.107473.","journal-title":"Int Immunopharmacol"},{"issue":"10","key":"2289_CR29","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1158\/1078-0432.CCR-13-2702","volume":"20","author":"KA Schalper","year":"2014","unstructured":"Schalper KA, Velcheti V, Carvajal D, Wimberly H, Brown J, Pusztai L, Rimm DL. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res. 2014;20(10):2773\u201382. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2702.","journal-title":"Clin Cancer Res"},{"key":"2289_CR30","doi-asserted-by":"publisher","unstructured":"Chen D, Li G, Ji C, et al. Enhanced B7-H4 expression in gliomas with low PD-L1 expression identifies super-cold tumors. J Immunother Cancer. 2020;8(1). https:\/\/doi.org\/10.1136\/jitc-2019-000154.","DOI":"10.1136\/jitc-2019-000154"},{"issue":"17","key":"2289_CR31","doi-asserted-by":"publisher","first-page":"5202","DOI":"10.1158\/1078-0432.CCR-16-3107","volume":"23","author":"M Altan","year":"2017","unstructured":"Altan M, Pelekanou V, Schalper KA, Toki M, Gaule P, Syrigos K, Herbst RS, Rimm DL. B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes. Clin Cancer Res. 2017;23(17):5202\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-3107.","journal-title":"Clin Cancer Res"},{"key":"2289_CR32","doi-asserted-by":"publisher","first-page":"149503","DOI":"10.1016\/j.gene.2025.149503","volume":"959","author":"C Baris Mogul","year":"2025","unstructured":"Baris Mogul C, Duran MB, Caner V, Turk NS, Tuncay OL. The PD-L1 Promoter Methylation Predicts Gene And Protein Expression Levels in Urothelial Carcinoma. Gene. 2025;959:149503. https:\/\/doi.org\/10.1016\/j.gene.2025.149503.","journal-title":"Gene"},{"key":"2289_CR33","doi-asserted-by":"publisher","first-page":"6910","DOI":"10.1038\/ncomms7910","volume":"6","author":"R Pathania","year":"2015","unstructured":"Pathania R, Ramachandran S, Elangovan S, et al. DNMT1 is essential for mammary and cancer stem cell maintenance and tumorigenesis. Nat Commun. 2015;6:6910. https:\/\/doi.org\/10.1038\/ncomms7910.","journal-title":"Nat Commun"},{"issue":"1","key":"2289_CR34","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/ng1068","volume":"33","author":"MF Robert","year":"2003","unstructured":"Robert MF, Morin S, Beaulieu N, Gauthier F, Chute IC, Barsalou A, MacLeod AR. DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat Genet. 2003;33(1):61\u20135. https:\/\/doi.org\/10.1038\/ng1068.","journal-title":"Nat Genet"},{"issue":"1","key":"2289_CR35","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s13148-021-01154-x","volume":"13","author":"C Hu","year":"2021","unstructured":"Hu C, Liu X, Zeng Y, Liu J, Wu F. DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: mechanism and clinical application. Clin Epigenetics. 2021;13(1):166. https:\/\/doi.org\/10.1186\/s13148-021-01154-x.","journal-title":"Clin Epigenetics"},{"issue":"1","key":"2289_CR36","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13148-018-0589-6","volume":"10","author":"R Deng","year":"2018","unstructured":"Deng R, Zhang P, Liu W, et al. HDAC is indispensable for IFN-gamma-induced B7-H1 expression in gastric cancer. Clin Epigenetics. 2018;10(1):153. https:\/\/doi.org\/10.1186\/s13148-018-0589-6.","journal-title":"Clin Epigenetics"},{"issue":"4","key":"2289_CR37","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/PPO.0000000000000061","volume":"20","author":"MF Sanmamed","year":"2014","unstructured":"Sanmamed MF, Chen L. Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation. Cancer J. 2014;20(4):256\u201361. https:\/\/doi.org\/10.1097\/PPO.0000000000000061.","journal-title":"Cancer J"},{"issue":"3","key":"2289_CR38","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41577-021-00566-3","volume":"22","author":"AM Gocher","year":"2022","unstructured":"Gocher AM, Workman CJ, Vignali DAA. Interferon-gamma: teammate or opponent in the tumour microenvironment? Nat Rev Immunol. 2022;22(3):158\u201372. https:\/\/doi.org\/10.1038\/s41577-021-00566-3.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"2289_CR39","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jdermsci.2005.06.008","volume":"40","author":"SK Lee","year":"2005","unstructured":"Lee SK, Seo SH, Kim BS, Kim CD, Lee JH, Kang JS, Maeng PJ, Lim JS. IFN-gamma regulates the expression of B7-H1 in dermal fibroblast cells. J Dermatol Sci. 2005;40(2):95\u2013103. https:\/\/doi.org\/10.1016\/j.jdermsci.2005.06.008.","journal-title":"J Dermatol Sci"},{"issue":"3","key":"2289_CR40","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.febslet.2005.12.093","volume":"580","author":"SJ Lee","year":"2006","unstructured":"Lee SJ, Jang BC, Lee SW, et al. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274). FEBS Lett. 2006;580(3):755\u201362. https:\/\/doi.org\/10.1016\/j.febslet.2005.12.093.","journal-title":"FEBS Lett"},{"issue":"6","key":"2289_CR41","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nri2326","volume":"8","author":"W Zou","year":"2008","unstructured":"Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8(6):467\u201377. https:\/\/doi.org\/10.1038\/nri2326.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"2289_CR42","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.immuni.2018.03.018","volume":"48","author":"J Li","year":"2018","unstructured":"Li J, Lee Y, Li Y, et al. Co-inhibitory Molecule B7 Superfamily Member 1 Expressed by Tumor-Infiltrating Myeloid Cells Induces Dysfunction of Anti-tumor CD8(+) T Cells. Immunity. 2018;48(4):773\u2013e786775. https:\/\/doi.org\/10.1016\/j.immuni.2018.03.018.","journal-title":"Immunity"},{"issue":"1","key":"2289_CR43","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3233\/BD-249006","volume":"43","author":"SA Syamsu","year":"2024","unstructured":"Syamsu SA, Faruk M, Smaradania N, Sampepajung E, Pranoto AS, Irsandy F, Tammasse IFU. PD-1\/PD-L1 pathway: Current research in breast cancer. Breast Dis. 2024;43(1):79\u201392. https:\/\/doi.org\/10.3233\/BD-249006.","journal-title":"Breast Dis"},{"key":"2289_CR44","doi-asserted-by":"publisher","unstructured":"Oshi M, Asaoka M, Tokumaru Y, Yan L, Matsuyama R, Ishikawa T, Endo I, Takabe K. CD8 T Cell Score as a Prognostic Biomarker for Triple Negative Breast Cancer. Int J Mol Sci. 2020;21(18). https:\/\/doi.org\/10.3390\/ijms21186968.","DOI":"10.3390\/ijms21186968"},{"issue":"11","key":"2289_CR45","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1038\/s12276-023-01105-x","volume":"55","author":"CH Koh","year":"2023","unstructured":"Koh CH, Lee S, Kwak M, Kim BS, Chung Y. CD8 T-cell subsets: heterogeneity, functions, and therapeutic potential. Exp Mol Med. 2023;55(11):2287\u201399. https:\/\/doi.org\/10.1038\/s12276-023-01105-x.","journal-title":"Exp Mol Med"},{"issue":"3","key":"2289_CR46","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1093\/jnci\/djad254","volume":"116","author":"CI Lee","year":"2024","unstructured":"Lee CI, Elmore JG. Beyond survival: a closer look at lead-time bias and disease-free intervals in mammography screening. J Natl Cancer Inst. 2024;116(3):343\u20134. https:\/\/doi.org\/10.1093\/jnci\/djad254.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"2289_CR47","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s10549-019-05130-1","volume":"174","author":"ES Stovgaard","year":"2019","unstructured":"Stovgaard ES, Dyhl-Polk A, Roslind A, Balslev E, Nielsen D. PD-L1 expression in breast cancer: expression in subtypes and prognostic significance: a systematic review. Breast Cancer Res Treat. 2019;174(3):571\u201384. https:\/\/doi.org\/10.1007\/s10549-019-05130-1.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"2289_CR48","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s40425-019-0540-1","volume":"7","author":"D Carvajal-Hausdorf","year":"2019","unstructured":"Carvajal-Hausdorf D, Altan M, Velcheti V, Gettinger SN, Herbst RS, Rimm DL, Schalper KA. Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC). J Immunother Cancer. 2019;7(1):65. https:\/\/doi.org\/10.1186\/s40425-019-0540-1.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"2289_CR49","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s10147-014-0701-7","volume":"20","author":"Y Geng","year":"2015","unstructured":"Geng Y, Wang H, Lu C, Li Q, Xu B, Jiang J, Wu C. Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3\u2009+\u2009Tregs in gastric cancer and its clinical significance. Int J Clin Oncol. 2015;20(2):273\u201381. https:\/\/doi.org\/10.1007\/s10147-014-0701-7.","journal-title":"Int J Clin Oncol"},{"issue":"2","key":"2289_CR50","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1158\/1078-0432.CCR-16-0150","volume":"23","author":"KA Schalper","year":"2017","unstructured":"Schalper KA, Carvajal-Hausdorf D, McLaughlin J, et al. Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer. Clin Cancer Res. 2017;23(2):370\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0150.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2289_CR51","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/CJI.0000000000000384","volume":"44","author":"DJ Ralser","year":"2021","unstructured":"Ralser DJ, Klumper N, Gevensleben H, et al. Molecular and Immune Correlates of PDCD1 (PD-1), PD-L1 (CD274), and PD-L2 (PDCD1LG2) DNA Methylation in Triple Negative Breast Cancer. J Immunother. 2021;44(8):319\u201324. https:\/\/doi.org\/10.1097\/CJI.0000000000000384.","journal-title":"J Immunother"},{"key":"2289_CR52","doi-asserted-by":"publisher","first-page":"106889","DOI":"10.1016\/j.intimp.2020.106889","volume":"88","author":"TT Hao","year":"2020","unstructured":"Hao TT, Liao R, Lei DL, Hu GL, Luo F. Inhibition of B7-H4 promotes hepatocellular carcinoma cell apoptosis and autophagy through the PI3K signaling pathway. Int Immunopharmacol. 2020;88:106889. https:\/\/doi.org\/10.1016\/j.intimp.2020.106889.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"2289_CR53","doi-asserted-by":"publisher","first-page":"e28232","DOI":"10.1371\/journal.pone.0028232","volume":"7","author":"X Wang","year":"2012","unstructured":"Wang X, Hao J, Metzger DL, Ao Z, Chen L, Ou D, Verchere CB, Mui A, Warnock GL. B7-H4 Treatment of T Cells Inhibits ERK, JNK, p38, and AKT Activation. PLoS ONE. 2012;7(1):e28232. https:\/\/doi.org\/10.1371\/journal.pone.0028232.","journal-title":"PLoS ONE"},{"issue":"1","key":"2289_CR54","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s13071-022-05263-1","volume":"15","author":"X Sun","year":"2022","unstructured":"Sun X, Xie H, Zhang H, et al. B7-H4 reduction induced by Toxoplasma gondii infection results in dysfunction of decidual dendritic cells by regulating the JAK2\/STAT3 pathway. Parasit Vectors. 2022;15(1):157. https:\/\/doi.org\/10.1186\/s13071-022-05263-1.","journal-title":"Parasit Vectors"},{"issue":"12","key":"2289_CR55","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1038\/s41419-017-0015-6","volume":"8","author":"N Xie","year":"2017","unstructured":"Xie N, Cai JB, Zhang L, et al. Upregulation of B7-H4 promotes tumor progression of intrahepatic cholangiocarcinoma. Cell Death Dis. 2017;8(12):3205. https:\/\/doi.org\/10.1038\/s41419-017-0015-6.","journal-title":"Cell Death Dis"},{"issue":"3","key":"2289_CR56","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1182\/blood-2005-08-007377","volume":"108","author":"Q Zhang","year":"2006","unstructured":"Zhang Q, Wang HY, Woetmann A, Raghunath PN, Odum N, Wasik MA. STAT3 induces transcription of the DNA methyltransferase 1 gene (DNMT1) in malignant T lymphocytes. Blood. 2006;108(3):1058\u201364. https:\/\/doi.org\/10.1182\/blood-2005-08-007377.","journal-title":"Blood"},{"key":"2289_CR57","doi-asserted-by":"publisher","unstructured":"Kim E, Ahuja A, Kim MY, Cho JY. DNA or Protein Methylation-Dependent Regulation of Activator Protein-1 Function. Cells. 2021;10(2). https:\/\/doi.org\/10.3390\/cells10020461.","DOI":"10.3390\/cells10020461"},{"key":"2289_CR58","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.semcancer.2019.04.001","volume":"59","author":"Q Yang","year":"2019","unstructured":"Yang Q, Jiang W, Hou P. Emerging role of PI3K\/AKT in tumor-related epigenetic regulation. Semin Cancer Biol. 2019;59:112\u201324. https:\/\/doi.org\/10.1016\/j.semcancer.2019.04.001.","journal-title":"Semin Cancer Biol"},{"key":"2289_CR59","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/1471-2407-7-158","volume":"7","author":"I Garcia-Tunon","year":"2007","unstructured":"Garcia-Tunon I, Ricote M, Ruiz AA, Fraile B, Paniagua R, Royuela M. Influence of IFN-gamma and its receptors in human breast cancer. BMC Cancer. 2007;7:158. https:\/\/doi.org\/10.1186\/1471-2407-7-158.","journal-title":"BMC Cancer"},{"key":"2289_CR60","doi-asserted-by":"publisher","unstructured":"Alspach E, Lussier DM, Schreiber RD. Interferon gamma and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity. Cold Spring Harb Perspect Biol. 2019;11(3). https:\/\/doi.org\/10.1101\/cshperspect.a028480.","DOI":"10.1101\/cshperspect.a028480"},{"key":"2289_CR61","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3389\/fimmu.2018.00847","volume":"9","author":"F Castro","year":"2018","unstructured":"Castro F, Cardoso AP, Goncalves RM, Serre K, Oliveira MJ. Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion. Front Immunol. 2018;9:847. https:\/\/doi.org\/10.3389\/fimmu.2018.00847.","journal-title":"Front Immunol"},{"issue":"9","key":"2289_CR62","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1038\/bjc.2015.101","volume":"112","author":"K Abiko","year":"2015","unstructured":"Abiko K, Matsumura N, Hamanishi J, et al. IFN-gamma from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer. 2015;112(9):1501\u20139. https:\/\/doi.org\/10.1038\/bjc.2015.101.","journal-title":"Br J Cancer"},{"issue":"1","key":"2289_CR63","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1186\/s13046-019-1403-9","volume":"38","author":"A Thiem","year":"2019","unstructured":"Thiem A, Hesbacher S, Kneitz H, et al. IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression. J Exp Clin Cancer Res. 2019;38(1):397. https:\/\/doi.org\/10.1186\/s13046-019-1403-9.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"2289_CR64","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/cas.13424","volume":"109","author":"K Mimura","year":"2018","unstructured":"Mimura K, Teh JL, Okayama H, et al. PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer. Cancer Sci. 2018;109(1):43\u201353. https:\/\/doi.org\/10.1111\/cas.13424.","journal-title":"Cancer Sci"},{"issue":"1","key":"2289_CR65","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/PPO.0000000000000303","volume":"24","author":"TS Nowicki","year":"2018","unstructured":"Nowicki TS, Hu-Lieskovan S, Ribas A. Mechanisms of Resistance to PD-1 and PD-L1 Blockade. Cancer J. 2018;24(1):47\u201353. https:\/\/doi.org\/10.1097\/PPO.0000000000000303.","journal-title":"Cancer J"},{"issue":"4","key":"2289_CR66","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/ijc.31357","volume":"143","author":"Y Gao","year":"2018","unstructured":"Gao Y, Yang J, Cai Y, Fu S, Zhang N, Fu X, Li L. IFN-gamma-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling. Int J Cancer. 2018;143(4):931\u201343. https:\/\/doi.org\/10.1002\/ijc.31357.","journal-title":"Int J Cancer"},{"key":"2289_CR67","doi-asserted-by":"publisher","unstructured":"Patnaik E, Madu C, Lu Y. Epigenetic Modulators as Therapeutic Agents in Cancer. Int J Mol Sci. 2023;24(19). https:\/\/doi.org\/10.3390\/ijms241914964.","DOI":"10.3390\/ijms241914964"},{"issue":"1","key":"2289_CR68","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s40164-022-00356-0","volume":"11","author":"M Dai","year":"2022","unstructured":"Dai M, Liu M, Yang H, Kucuk C, You H. New insights into epigenetic regulation of resistance to PD-1\/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities. Exp Hematol Oncol. 2022;11(1):101. https:\/\/doi.org\/10.1186\/s40164-022-00356-0.","journal-title":"Exp Hematol Oncol"},{"issue":"41","key":"2289_CR69","doi-asserted-by":"publisher","first-page":"6752","DOI":"10.1038\/s41388-019-0919-y","volume":"38","author":"D Feng","year":"2019","unstructured":"Feng D, Qin B, Pal K, et al. BRAF(V600E)-induced, tumor intrinsic PD-L1 can regulate chemotherapy-induced apoptosis in human colon cancer cells and in tumor xenografts. Oncogene. 2019;38(41):6752\u201366. https:\/\/doi.org\/10.1038\/s41388-019-0919-y.","journal-title":"Oncogene"},{"key":"2289_CR70","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.gene.2017.04.003","volume":"623","author":"H Huang","year":"2017","unstructured":"Huang H, Li C, Ren G. Clinical significance of the B7-H4 as a novel prognostic marker in breast cancer. Gene. 2017;623:24\u20138. https:\/\/doi.org\/10.1016\/j.gene.2017.04.003.","journal-title":"Gene"},{"issue":"3","key":"2289_CR71","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/s41416-019-0511-9","volume":"121","author":"DW Lee","year":"2019","unstructured":"Lee DW, Ryu HS, Jin MS, et al. Immune recurrence score using 7 immunoregulatory protein expressions can predict recurrence in stage I-III breast cancer patients. Br J Cancer. 2019;121(3):230\u20136. https:\/\/doi.org\/10.1038\/s41416-019-0511-9.","journal-title":"Br J Cancer"},{"issue":"2","key":"2289_CR72","doi-asserted-by":"publisher","first-page":"e000150","DOI":"10.1136\/esmoopen-2016-000150","volume":"2","author":"A Kitano","year":"2017","unstructured":"Kitano A, Ono M, Yoshida M, et al. Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer. ESMO Open. 2017;2(2):e000150. https:\/\/doi.org\/10.1136\/esmoopen-2016-000150.","journal-title":"ESMO Open"},{"issue":"12","key":"2289_CR73","doi-asserted-by":"publisher","first-page":"e954868","DOI":"10.4161\/21624011.2014.954868","volume":"3","author":"YJ Kim","year":"2014","unstructured":"Kim YJ. Subverting the adaptive immune resistance mechanism to improve clinical responses to immune checkpoint blockade therapy. Oncoimmunology. 2014;3(12):e954868. https:\/\/doi.org\/10.4161\/21624011.2014.954868.","journal-title":"Oncoimmunology"},{"issue":"4","key":"2289_CR74","doi-asserted-by":"publisher","first-page":"e313","DOI":"10.1093\/oncolo\/oyab063","volume":"27","author":"Y Ni","year":"2022","unstructured":"Ni Y, Tsang JY, Shao Y, Poon IK, Tam F, Shea KH, Tse GM. Combining Analysis of Tumor-infiltrating Lymphocytes (TIL) and PD-L1 Refined the Prognostication of Breast Cancer Subtypes. Oncologist. 2022;27(4):e313\u201327. https:\/\/doi.org\/10.1093\/oncolo\/oyab063.","journal-title":"Oncologist"},{"issue":"5","key":"2289_CR75","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1136\/gutjnl-2015-310839","volume":"66","author":"ED Thompson","year":"2017","unstructured":"Thompson ED, Zahurak M, Murphy A, et al. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut. 2017;66(5):794\u2013801. https:\/\/doi.org\/10.1136\/gutjnl-2015-310839.","journal-title":"Gut"},{"issue":"1","key":"2289_CR76","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1038\/s41467-023-37807-z","volume":"14","author":"DJ Kim","year":"2023","unstructured":"Kim DJ, Anandh S, Null JL, et al. Priming a vascular-selective cytokine response permits CD8(+) T-cell entry into tumors. Nat Commun. 2023;14(1):2122. https:\/\/doi.org\/10.1038\/s41467-023-37807-z.","journal-title":"Nat Commun"},{"issue":"7577","key":"2289_CR77","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature15520","volume":"527","author":"D Peng","year":"2015","unstructured":"Peng D, Kryczek I, Nagarsheth N, et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature. 2015;527(7577):249\u201353. https:\/\/doi.org\/10.1038\/nature15520.","journal-title":"Nature"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-026-02289-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02289-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02289-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T01:29:22Z","timestamp":1780622962000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-026-02289-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2289"],"URL":"https:\/\/doi.org\/10.1186\/s13058-026-02289-6","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"30 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All procedures performed in studies involving human paraffin-embedded tissues and human peripheral mononuclear cells were obtained in accordance with the institutional policies. All protocols were reviewed and approved by the Ethical Committee of Fujian Medical University (2021-NO.194).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"106"}}